(GMAB) Genmab AS - Overview
Stock: Antibody Therapeutics, Cancer, Lymphoma, Multiple Myeloma, Solid Tumors
| Risk 5d forecast | |
|---|---|
| Volatility | 34.1% |
| Relative Tail Risk | -0.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.07 |
| Alpha | 42.10 |
| Character TTM | |
|---|---|
| Beta | 0.617 |
| Beta Downside | 0.447 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.13% |
| CAGR/Max DD | -0.16 |
EPS (Earnings per Share)
Revenue
Description: GMAB Genmab AS February 13, 2026
Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotech that builds antibody-based therapeutics, primarily for oncology and immune-mediated diseases. Its commercial portfolio includes EPKINLY and TEPKINLY for relapsed/refractory large-B-cell lymphomas, Tivdak for metastatic cervical cancer, and a suite of collaborations that give it rights to products such as DARZALEX, RYBREVANT, and Kesimpta. The pipeline spans late-stage candidates-Epcoritamab (B-cell malignancies), tisotumab vedotin (solid tumors), and Mim8 (hemophilia A)-as well as early-stage assets targeting solid tumors, NSCLC, and rare diseases.
Key recent metrics (FY 2025): revenue $2.1 billion, up 23 % YoY driven by Tivdak’s global launch and expanding sales of DARZALEX; net loss $200 million, reflecting continued R&D spend; cash and equivalents $1.8 billion, providing runway into 2029. The Phase 3 EPCORE™ trial for Epcoritamab met its primary endpoint in October 2025, positioning it for potential FDA submission in 2026. The biotech sector is benefitting from a 9 % CAGR in oncology drug spending and a 4 % rise in global R&D intensity, which supports higher valuation multiples for companies with late-stage oncology assets.
For a deeper quantitative assessment of GMAB’s valuation relative to peers, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 6.57b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.41 > 0.02 and ΔFCF/TA 31.30 > 1.0 |
| NWC/Revenue: 26.57% < 20% (prev 164.8%; Δ -138.2% < -1%) |
| CFO/TA 0.46 > 3% & CFO 3.21b > Net Income 6.57b |
| Net Debt (-1.62b) to EBITDA (5.96b): -0.27 < 3 |
| Current Ratio: 6.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (620.7m) vs 12m ago -4.33% < -2% |
| Gross Margin: 94.31% > 18% (prev 0.96%; Δ 9335 % > 0.5%) |
| Asset Turnover: 60.15% > 50% (prev 29.25%; Δ 30.90% > 0%) |
| Interest Coverage Ratio: 48.21 > 6 (EBITDA TTM 5.96b / Interest Expense TTM 119.0m) |
Altman Z'' 10.00
| A: 0.53 (Total Current Assets 4.47b - Total Current Liabilities 741.0m) / Total Assets 7.02b |
| B: 0.57 (Retained Earnings 4.03b / Total Assets 7.02b) |
| C: 0.25 (EBIT TTM 5.74b / Avg Total Assets 23.34b) |
| D: 3.02 (Book Value of Equity 3.84b / Total Liabilities 1.27b) |
| Altman-Z'' Score: 10.18 = AAA |
Beneish M -3.13
| DSRI: 0.14 (Receivables 1.05b/6.31b, Revenue 14.04b/11.60b) |
| GMI: 1.02 (GM 94.31% / 96.09%) |
| AQI: 0.91 (AQ_t 0.33 / AQ_t-1 0.36) |
| SGI: 1.21 (Revenue 14.04b / 11.60b) |
| TATA: 0.48 (NI 6.57b - CFO 3.21b) / TA 7.02b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of GMAB shares?
Over the past week, the price has changed by -2.82%, over one month by -11.34%, over three months by -0.69% and over the past year by +43.55%.
Is GMAB a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GMAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.9 | 26.3% |
| Analysts Target Price | 37.9 | 26.3% |
| ValueRay Target Price | 30.7 | 2.3% |
GMAB Fundamental Data Overview February 11, 2026
P/E Trailing = 13.5395
P/E Forward = 11.3766
P/S = 4.9447
P/B = 3.3097
P/EG = 0.6004
Revenue TTM = 14.04b DKK
EBIT TTM = 5.74b DKK
EBITDA TTM = 5.96b DKK
Long Term Debt = 142.0m DKK (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.0m DKK (from shortTermDebt, last quarter)
Debt = 142.0m DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.62b DKK (from netDebt column, last quarter)
Enterprise Value = 116.36b DKK (119.63b + Debt 142.0m - CCE 3.41b)
Interest Coverage Ratio = 48.21 (Ebit TTM 5.74b / Interest Expense TTM 119.0m)
EV/FCF = 40.00x (Enterprise Value 116.36b / FCF TTM 2.91b)
FCF Yield = 2.50% (FCF TTM 2.91b / Enterprise Value 116.36b)
FCF Margin = 20.72% (FCF TTM 2.91b / Revenue TTM 14.04b)
Net Margin = 46.80% (Net Income TTM 6.57b / Revenue TTM 14.04b)
Gross Margin = 94.31% ((Revenue TTM 14.04b - Cost of Revenue TTM 798.2m) / Revenue TTM)
Gross Margin QoQ = 94.32% (prev 93.84%)
Tobins Q-Ratio = 16.57 (Enterprise Value 116.36b / Total Assets 7.02b)
Interest Expense / Debt = 2.11% (Interest Expense 3.00m / Debt 142.0m)
Taxrate = 16.80% (81.0m / 482.0m)
NOPAT = 4.77b (EBIT 5.74b * (1 - 16.80%))
Current Ratio = 6.03 (Total Current Assets 4.47b / Total Current Liabilities 741.0m)
Debt / Equity = 0.02 (Debt 142.0m / totalStockholderEquity, last quarter 5.75b)
Debt / EBITDA = -0.27 (Net Debt -1.62b / EBITDA 5.96b)
Debt / FCF = -0.56 (Net Debt -1.62b / FCF TTM 2.91b)
Total Stockholder Equity = 27.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 28.15% (Net Income 6.57b / Total Assets 7.02b)
RoE = 23.97% (Net Income TTM 6.57b / Total Stockholder Equity 27.41b)
RoCE = 20.83% (EBIT 5.74b / Capital Employed (Equity 27.41b + L.T.Debt 142.0m))
RoIC = 36.00% (NOPAT 4.77b / Invested Capital 13.26b)
WACC = 8.18% (E(119.63b)/V(119.77b) * Re(8.19%) + D(142.0m)/V(119.77b) * Rd(2.11%) * (1-Tc(0.17)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.86%
[DCF Debug] Terminal Value 78.29% ; FCFF base≈3.35b ; Y1≈3.56b ; Y5≈4.23b
Fair Price DCF = 118.0 (EV 71.06b - Net Debt -1.62b = Equity 72.68b / Shares 616.0m; r=8.18% [WACC]; 5y FCF grow 6.66% → 2.90% )
EPS Correlation: 52.98 | EPS CAGR: 43.00% | SUE: 0.93 | # QB: 2
Revenue Correlation: -23.89 | Revenue CAGR: -22.19% | SUE: -0.97 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.157 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.49 | Chg30d=-0.027 | Revisions Net=+0 | Growth EPS=-22.2% | Growth Revenue=+15.8%